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Abstract
Purpose The aim of this study was to compare long-term effects of high-volume surgery at a single-center to multicenter 
use when using a mesh-capturing device for pelvic organ prolapse (POP) repair.
Methods Five years after surgery 101 (88%) at the single center were compared with 164 (81.2%) in the multicenter trial. 
Outcome measurements included clinical examination, prolapse-specific symptom questionnaires [Pelvic Floor Distress 
Inventory 20 (PFDI-20), Pelvic Floor Impact Questionnaire—short form (PFIQ-7), Pelvic Organ Prolapse/Urinary Inconti-
nence Sexual Questionnaire (PISQ-12)] and pain estimation by VAS (0–10).
Results Optimal apical segment outcome was 95% in the single- compared to 83.3% in the multicenter study (p < 0.001). POP 
recurrence in the anterior and posterior walls (POP-Q, Ba and Bp ≥ 0) was more common at the multicenter as compared to 
the single center [(19.8% vs 5.4%) and (26% vs 2.7%), (p < 0.001)]. Reoperations for POP and mesh-related complications 
were more frequent in the multicenter study [31/202 (15.3%) vs 7/116 (6.1%), p < 0.001]. Total PFDI-20, PFIQ-7 and PISQ-
12 scores were comparable between the cohorts. There were no significant differences in overall pain scores in-between the 
cohorts during follow-up. At the single center, 1/81 patients (1.2%) had VAS 7/10, i.e. severe pain, as compared to 3/131 
(2.3%) in the multicenter study (p = 0.277).
Conclusions Despite the high objective and subjective long-term effectiveness of the procedure in both regular use, and at a 
high-volume center, centralizing the use of a standardized capturing-device guided transvaginal mesh for POP repair reduced 
secondary interventions by more than half.
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Introduction
Pelvic reconstructive surgery using the transvaginal 
Uphold™ Lite mesh kit to suspend the apical vaginal seg-
ment has been shown to effectively ameliorate pelvic organ 
prolapse (POP) symptoms and restore anatomical outcomes 
at short term [1–8]. Due to a lack of “sufficient evidence to 
assure that the probable benefits of the devices outweigh 
their probable risks”, the FDA decided that vaginal mesh 
products should not be distributed in the US (FDA 2019) 
[9]. As a consequence, many mesh manufacturers discon-
tinued manufacturing and sales of the products worldwide. 
However, there is a continued need for investigating safety 
and effectiveness of transvaginal mesh devices since many 
patients who have already undergone the procedures are fac-
ing unknown long-term outcomes.
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It is well established that centralization of complex or 
high-risk procedures to high-volume centers may optimize 
outcomes, increase patient safety, decrease mortality and 
also increase cost-effectiveness [10–18]. In the field of pel-
vic reconstructive surgery, there is, however, scarce evidence 
to support this claim. As a consequence, it is not known how 
long-term outcomes and morbidity may differ between the 
settings [2, 4, 8]. Increased knowledge on the differences 
in outcomes between single- and multi-center use of surgi-
cal innovations in urogynecology may guide and improve 
the clinical introduction of new surgical procedures in the 
future. The aim of this study was to evaluate if high-volume 
center outcomes are superior to the results of regular use of 
Uphold mesh kit for apical prolapse at long term and how 
this relates to long-term morbidity of the procedure.
Materials and methods
For the purpose of the study, we combined data derived from 
two separate studies designed as a single- and a multi-center 
study [2, 4, 8]. These studies aimed to evaluate various clini-
cal aspects of the Uphold mesh kit. All patients included in 
this study had symptomatic and quantified apical segment 
(uterine or vaginal vault) prolapse ≥ stage 2, with or with-
out anterior vaginal wall prolapse, according to the pelvic 
organ prolapse quantification (POP-Q) system [19]. Ana-
tomical outcomes were assessed using the POP-Q system 
during a gynecological examination with the patient in a 
lithotomy position at which time mesh exposure or other 
healing defects were recorded. POP-Q stage 0 or 1 in the api-
cal compartment was considered an optimal anatomical out-
come and was the primary outcome measure for the analysis.
Using a standardized procedure with a capturing device, 
a monofilament, macroporous and uncoated polypropylene 
mesh (Uphold™ Lite) was placed to suspend the apical vagi-
nal segment [2, 4]. All patients at the single center were 
operated by two experienced urogynecological surgeons 
(50 and 65 patients, respectively) at the Department of 
Obstetrics and Gynecology, Danderyd Hospital, Stockholm, 
Sweden.
The multicenter study included a total of 207 patients 
operated by 26 surgeons at senior consultant level through-
out 24 centers in Sweden, Finland, Denmark and Norway 
[2, 8]. Data have been previously published and described 
in detail [2, 8]. The 24 centers were located as 11 centers 
at Sweden, 4 centers at Finland, 5 centers at Norway and 
4 centers at Denmark. The rate of surgery was from 1 to 
13 patients for each surgeon (mean 8 patients/surgeon) and 
1–24 patients for each center (mean 8.6 patients/center).
The study protocol was near identical for both studies and 
neither study was blinded [2, 4, 8]. Exclusion criteria for 
both studies included: current or previously treated pelvic 
organ cancer, cervical elongation, severe rheumatic disease, 
insulin-treated diabetes mellitus, connective tissue disorders, 
current systemic steroid treatment, and urinary incontinence. 
Follow-up after surgery was performed after 1 and 5 years in 
the multicenter study and 2 and 5 years in the single-center 
study. There were no restrictions on weight, parity, meno-
pausal status, or previous surgery although urinary incon-
tinence was not an exclusion criterion at the single center. 
In both studies, patients were included by the responsible 
urogynecologist if a patient fulfilled the inclusion and no 
exclusion criteria.
Subjective disease-specific pelvic floor outcomes were 
assessed by the Pelvic Floor Distress Inventory 20 (PFDI-
20) questionnaire which includes 3 scales of 20 questions: 
Urinary Distress Inventory-6 (UDI-6), Pelvic Organ Pro-
lapse Distress Inventory-6 (POPDI-6), and Colorectal-Anal 
Distress inventory-8 (CRADI-8) [20]. The Pelvic Floor 
Impact Questionnaire—short form (PFIQ-7) was used to 
assess effects on quality of life [20]. The PFIQ-7 includes the 
Urinary Impact Questionnaire (UIQ-7), the Colorectal-Anal 
Impact Questionnaire (CRAIQ-7) and the Pelvic Organ Pro-
lapse Impact Questionnaire (POPIQ-7) [20]. To measure the 
impact on patients’ sexual function, Pelvic Organ Prolapse/
Urinary Incontinence Sexual Questionnaire (PISQ-12) was 
used which includes 12 questions concerning behavioral/
emotional, physical and partner related sexual domains [21]. 
Additional surgical procedures, POP recurrence, as well as, 
interventions for mesh-related complications following the 
primary operation was registered up to 5 years after surgery.
A Visual Analogue Scale (VAS) was used to assess pel-
vic pain at baseline and follow-up visits [22]. The 11-point 
scale ranges from 0 to 10 where 0 indicates no pain and 10 
indicates maximal severe pain. In a sub-analysis of pain, we 
used the Numeric Rating Scale (NRS). The NRS for pain 
is classified into four categories; 0 indicates no pain, 1–3 
mild pain, 4–6 moderate pain, whereas 7–10 indicate severe 
pain [22].
Statistical analysis
Statistical analysis was performed using the predictive 
analysis software  (IBM@SPSS© Statistics, Version 25, 
Inc, Chicago, IL, USA, 2017). We used independent sam-
ple t tests to compare independent variables. The statisti-
cal difference between nominal data was tested by Chi-
square test of independence. Repeated measures ANOVA 
was used to test total values and to compare continued 
variables and over time of follow-up between the single 
and the multicenter. The General Linear Model of analysis 
was used to compare changes over time and centers when 
analyzing the NRS scale for pain. Inference for popula-
tion proportion analysis was used to statistically compare 
between proportions in the two different populations, i.e. 
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the single and multicenter. All missing data were consid-
ered as missing without imputation of data.
Ethical approval
The studies were approved by the Stockholm Regional 
Ethical Review Board and ethic review committees in the 
respective countries as appropriate.
The single-center and the multicenter studies were 
registered at www.clini caltr ials.gov: NCT03077490 and 
NCT01823055 respectively.
Results
Five years after surgery, 101/115 (88%) and 164/207 (79%) 
patients answered the patient-reported outcome question-
naires at the single and multicenter, respectively. 74/115 
patients (64.3%) at the single-center and 139/207 patients 
(67.1%) at the multicenter trial were available for clinical 
examination and POP-Q evaluation.
Anatomical outcomes and POP-Q staging at 5 years after 
surgery are described in Table 1. An optimal anatomical 
apical segment outcome (POP-Q C stage 0–1) was achieved 
in 97.3% (72/74 patients) in the single-center cohort as 
compared to 97.5% (116/119) in the multicenter cohort 
Table 1  5-year evaluation of 
anatomical outcomes following 
the Uphold procedure
p value for apical, anterior and posterior wall compare success (POP-Q stage 0–1) vs failure (POP-Q stage 
2–4). p < 0.05 was considered statistically significant (Chi-square test)
POP-Q stage/compartment Stage Multicenter Single center p value
n (%) n n (%) n
Apical (C) 0 45 (38%) 119 7 /10%) 74 0.938 [98% vs 97%
1 71 (60%) 65 (88%) (116/119) vs (72/74)]
2 1 (1%) 1 (1%)
3 2 (2%) 1 (1%)
4 0 0
Anterior wall (Aa) 0 52 (39%) 131 38 (51%) 74 0.002 [69% vs 92%
1 41 (31%) 30 (41%) (91/131) vs (67/74)]
2 38 (28%) 4 (5%)
3 3 (2%) 2 (3%)
4 0 (0%) 0 (0%)
Anterior wall (Ba) 0 38 (29%) 131 50 (68%) 74  < 0.001 [70% vs 91%
1 53 (41%) 17 (23%) (91/131) vs (67/74)]
2 36 (28%) 3 (4%)
3 4 (3%) 4 (5%)
4 0 (0%) 0 (0%)
Posterior wall (Ap) 0 19 (15%) 131 32 (43%) 74  < 0.001 [61% vs 92%
1 61 (47%) 36 (49%) (80/131) vs (68/74)]
2 47 (36%) 5 (7%)
3 4 (3%) 1 (1%)
4 0 (0%) 0 (0%)
Posterior wall (Bp) 0 33 (25%) 131 48 (65%) 74  < 0.001 [55% vs 89%
1 39 (30%) 18 (24%) (72/131) vs (66/74)]
2 52 (40%) 6 (8%)
3 6 (5%) 2 (3%)
4 1 (1%) 0 (0%)




74 0. 005 [20% vs 5%]




74  < 0.001 [26% vs 3%]
Pb (mean ± SD) 3.3 ± 0.9
(CI 3.2–3.5)
129 2.8 ± 0.7
(CI 2.7–3)
73  < 0.001
Gh (mean ± SD) 3.9 ± 0.9
(CI 3.8–4.1)
129 4 ± 1.0
(CI 3.8–4.3)
73 0.402
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(p = 0.938). If considering patients re-operated by any POP 
surgical procedure during follow-up as a failure, i.e. an opti-
mal outcome (POP-Q stage 0–1 in the apical segment) and 
no secondary procedures the success rate was 95% (70/74) 
in the single-center and 83.3% (116/139) in the multicenter 
cohort (p < 0.001). When considering the anterior and poste-
rior vaginal compartments separately, occurrence of anterior 
vaginal wall prolapse (POP-Q Ba ≥ 0) was 5.4% (4/74) in 
the single-center cohort vs. 19.8% (26/131) in the multi-
center cohort (p < 0.001). For posterior vaginal wall pro-
lapse (POP-Q Bp ≥ 0), the corresponding figures were 2.7% 
(2/74) vs. 26% (34/131) (p < 0.001). Other individual POP-Q 
items were largely comparable between the cohorts. There 
were no cases of mesh erosion (0/74) in the single-center 
study as compared to 3/139 (2.2%) in the multicenter study 
(p = 0.034).
Total number of surgical interventions for pelvic floor 
insufficiency or mesh-related complications was 7/115 
patients (6.1%) vs. 31/202 patients (15.3%) in the single- and 
multicenter cohorts, respectively, during the 5-years follow-
up (p = 0.001). Four patients were re-operated because of 
postoperative pain (4/164, 2.4%) at the multicenter vs. none 
at the single center (p = 0.021). At the time of surgery, the 
mesh was removed in all four cases and in one case, a hys-
terectomy was performed.
There were no significant differences in demographic 
characteristics between the single and multicenter 
(Table 2). There were no significant differences between 
the cohorts in subjective outcomes, i.e. patient-reported 
symptoms as measured by the PFIQ-7, PFDI-20, PISQ-12 
(Table 1). Although the UDI-6 domain score was higher in 
the single center (23.6 ± 19.61 vs. 17.2 ± 18.28, p = 0.01), 
indicating greater symptom severity of urinary incon-
tinence, it did not significantly affect the total PFDI-20 
score. The PISQ physical domain was significantly higher 
at the single center (17.7 ± 2.72 vs. 14.1 ± 3.48, p < 0.001), 
indicating higher sexual activity, whereas the PISQ-part-
ner domain was lower at the single center (7.2 ± 2.51 vs. 
10.09 ± 2.79, p < 0.001) indicating lower partner sexual 
activity. Neither of these differences affected the total 
PISQ-12 score.
In an analysis of changes over time, we performed pair-
wise comparisons of changes in reported pain outcomes 
and patient-reported pelvic floor questionnaires (PFIQ-7 
and PFDI-20) if individual patient data were available 
at the two follow-up times (Table 3). There were no sig-
nificant differences noticed when comparing changes in 
patient-reported outcomes between the cohorts. There 
was an insufficient number of pairwise observations with 
completed PISQ-12 scores to allow for a valid comparison 
between the cohorts over time.
Table 4 shows pain-related outcomes following sur-
gery. The previously reported short-term improvements 
in patient reported pain was sustained at the 5-years fol-
low-up after surgery in both cohorts (p < 0.001). Further-
more, there were no significant differences in estimated 
pain scores (VAS) in-between the cohorts during follow-
up (independent-sample t test). At the single center, 1/81 
patients (1.2%) had VAS 7/10, i.e. severe pain, as com-
pared to 3/131 (2.3%) in the multicenter study (p = 0.277) 
based on the NRS scale.
Table 2  5-year data comparing 
subjective outcomes in a single 
vs. multicenter study
Independent sample t test, p < 0.05 was considered statistically significant
Multi-center Single-center p value
Mean ± SD CI n Mean ± SD CI n
Age (years) 69.8 ± 11 68–71.7 138 70.8 ± 9.3 69.0–72.7 94 0.46
Weight (kg) 71 ± 10.3 69.1–73 110 70.8 ± 11 68.1–73.5 65 0.91
BMI 25.7 ± 5.9 24.6–26.8 111 26.1 ± 3.5 25.2–26.9 65 0.61
Pain (VAS scale) 0.4 ± 1.1 0.2–0.6 131 0.6 ± 1.38 0.2–0.9 81 0.29
PFIQ-7 total 13.7 ± 31.7 8.8–18.6 164 18.4 ± 32.8 11–25.7 79 0.29
PFIQ- UIQ7 6.4 ± 15.2 4.1–8.7 170 7.7 ± 14.2 4.5–10.1 80 0.52
PFIQ- CRAIQ7 4.4 ± 11.4 2.6–6.1 164 6.7 ± 14.3 3.5–9.9 79 0.17
PFIQ- POPIQ7 3.3 ± 10.1 1.7–4.8 166 4 ± 11 1.5–6.4 79 0.62
PFDI-20 47.4 ± 40.5 39.8–53.1 146 56.1 ± 44 45.5–66.7 69 0.11
POPDI-6 12.1 ± 15.2 9.7–14.5 156 15.9 ± 15.8 12.3–19.6 74 0.08
CRADI-8 14.4 ± 14.3 12.2–16.7 155 17.7 ± 17.6 13.6–21.8 73 0.12
UDI-6 17.2 ± 18.3 14.3–20.1 155 23.6 ± 19.6 19.2–28 78 0.01
PISQ-12 total 33.4 ± 8.1 31.4–35.4 66 34.6 ± 6.1 32.2–36.9 28 0.49
PISQ12-behavioral 8.3 ± 3.8 7.3–9.2 67 8.2 ± 4.2 6.8–9.6 35 0.95
PISQ-physical 14.1 ± 3.5 13.3–15 66 17.7 ± 2.7 16.7–18.6 35  < 0.001
PISQ- partner 10.09 ± 2.8 10.2–11.6 66 7.2 ± 2.5 6.3–8.1 31  < 0.001
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Discussion
In this 5-years analysis which combined data from two 
separate cohort studies using the  UpholdLite mesh device 
for POP reconstructive surgery, we found that single-
center high-surgery volumes resulted in less reoperations 
for POP recurrence and fewer mesh-related complications 
requiring surgical intervention. There were, however, no 
significant differences between the cohorts with regard 
to patient-reported outcomes. A number of studies have 
shown that the  UpholdLite procedure for apical prolapse 
provide satisfactory subjective and objective outcomes and 
that high surgical volumes result in short-term decreased 
complication rates following apical mesh augmented sur-
gery [1–8]. However, long-term efficacy and safety data 
have been missing.
Overall, we found that anatomical outcomes were sus-
tainable over time with only minor, and non-significant, 
differences when comparing short and long-term follow-
up both with regard to anatomical and patient-reported 
outcomes. When comparing the single- to the multi-center 
cohort 5 years after surgery, we also found no significant 
differences in our primary outcome (restoration of apical 
Table 3  Pairwise comparison of 
changes over time
Independent sample t test was used for statistical analysis
Only patients with completed data collected at 1–2 years and 5 years after surgery were included in the 
analysis
Multi-center Single-center p value
Mean ± SD CI n Mean ± SD CI n
Age (years) 3.9 ± 6.2 2.8 to 4.9 80 4.4 ± 1.8 4.0 to 4.7 78 0.440
Weight (kg) 0.9 ± 6.3 − 0.3 to 2.1 107 − 0.3 ± 3.6 − 1.2 to 0.6 64 0.176
BMI 0 ± 4.6 − 0.9 to 0.9 105 0 ± 1.4 − 0.4 to 0.3 63 0.924
Pain (VAS scale) 0 ± 0.5 − 0.1 to 0.1 106 0 ± 1.3 − 0.2 to 0.3 62 0.176
PFIQ- 7 total − 12.70 ± 26 − 17 to − 8.2 131 − 7.5 ± 27.7 − 13.8 to − 1.1 76 0.190
PFIQ- UIQ7 − 3.2 ± 12.5 − 5.3 to − 1.1 138 − 1.9 ± 12 − 4.5 to 0.8 79 0.452
PFIQ- CRAIQ7 − 4.1 ± 9.93 − 5.8 to − 2.4 131 − 1.8 ± 12 − 4.5 to 0.9 77 0.145
PFIQ- POPIQ7 − 5.4 ± 7.38 − 6.7 to − 4.2 134 − 4.1 ± 9.7 − 6.3 to − 1.9 76 0.258
PFDI-20 2.3 ± 39.5 − 4.8 to 9.5 119 − 3.9 ± 35 − 12.5 to 4.7 66 0.284
POPDI-6 − 1.6 ± 20.1 − 5.2 to 1.9 126 − 1.4 ± 17.3 − 5.4 to 2.6 75 0.157
CRADI-8 0 ± 15.6 − 2.7 to 2.8 126 2.9 ± 15.1 − 0.7 to 6.5 70 0.220
UDI- 6 0.1 ± 16.3 − 2.8 to 2.9 127 − 3.3 ± 15.9 − 7.1 to 0.4 71 0.933
Table 4  Analysis of pain before and after surgery
ANOVA repeated measures was used for analysis of VAS-scale
# Using the general linear model of analysis, pain estimated by the NRS at both trials was significantly improved overtime (p = 0.001) and there 
was no significance between the two studies (p = 0.205)
¥ One patient had complicated laparoscopic operation 3 years after primary surgery
† Patient had Paracetamol/Codeine treated low back pain at least 2 years before primary surgery with the mesh and continued with same treat-
ment after surgery













VAS-scale (0–10) 1 ± 1.8 (CI: 
0.8–1.3)
1.1 ± 2 (CI: 
0.7–1.5)
0.3 ± 0.9 (CI: 
0.2–0.5)
0.5 ± 1.3 (CI: 
0.2–0.8)
0.4 ± 1.2 (CI: 
0.2–0.6)




 No pain (0) 140 (74%) 66 (65%) 122 (93%) 84 (83%) 122 (92%) 65 (80%) #
 Mild pain (1–3) 35 (18%) 22 (22%) 8 (6%) 12 (12%) 7 (5%) 13 (16%)
 Moderate pain 
(4–6)
12 (6) 9 (9%) 0 (0%) 2 (3%) 0 (0%) 3 (4%)¥
 Severe pain 
(7–10)
3 (2%) 4 (4%) 1 (1%) 2 (2%) 3 (2%) 1 (1%)†
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support) or in overall subjective scores with regard to condi-
tion specific symptoms, quality of life and sexual function. 
There was, however, a significant difference with regard to 
the occurrence of reoperations of both mesh-related com-
plications and secondary pelvic reconstructive surgery, to 
the advantage of single-center use. The overall risk ratio 
for any complication in the multi-center compared to the 
single-center setting was 1.5:1 in patients undergoing the 
Uphold procedure as first-time prolapse surgery and 4:1 in 
patients undergoing surgery for recurrence in a previously 
operated compartment. These results suggest that a high 
surgical volume is beneficial for patients also at long term 
and that the risk for mesh-related complications requiring 
removal or revision of the mesh decreases with increased 
surgical experience. There is no universally accepted defini-
tion of high surgical volume and the number considered as 
high-volume certainly varies between different procedures. 
There is, however, a clear link between volume and patient 
morbidity, as well as, mortality in many fields. In concur-
rence with our results, a study by De Tayrac et al. showed a 
negative association between an increasing number of pelvic 
organ prolapse mesh procedures performed and the rate of 
complications [23]. Thus, emerging data suggest that the 
assumed relationship between volume and morbidity is valid 
also for urogynecological mesh surgery.
Subjective outcomes overall were improved also at long 
term when compared to baseline and largely sustained com-
pared to the short-term outcomes. This was true also for per-
ceived pain. Given recent years of widespread attention and 
highlighting of pain complications related to the use of vagi-
nal mesh, it was somewhat surprising that levels of experi-
enced pelvic pain in both the single- and multi-center cohort 
5 years after surgery was low in general and still signifi-
cantly lower than at baseline. We nonetheless recognize that 
long-term severe pain complications did occur and afflicted 
one and three patients in the single- and multi-center study, 
respectively. The mechanisms for mesh-related pain after 
biomaterial augmented surgery, although poorly understood, 
may be caused by a wide range of factors including differ-
ent modes and routes of surgery, surgical dissection prior 
to placing the mesh, bleeding, infection, and pre-existing 
pain. The management of patients who experience persis-
tent pain after mesh surgery remains clinically challenging 
and deserves further attention given our lack of knowledge 
on long-term consequences of mesh procedures, although 
many previously used products are no longer commercially 
available worldwide.
Three cases of mesh exposure were as reported in the 
multicenter cohort at the 5-years follow up, whereas none 
was reported in the single-center study. None of the three 
cases of mesh exposure reported persistent pain and were 
treated conservatively with topical estrogen without addi-
tional surgical interventions. Although suggested by our 
data, and supported by other studies [24–27], there was an 
insufficient number of cases to determine if high-volume 
single-center use was beneficial also with regard to postop-
erative mesh exposure at long term. Regardless, our long-
term clinical data on more than 200 patients suggest that 
mesh exposure seems to be a relatively minor problem at 
long-term following this specific procedure and can be 
handled conservatively.
Despite early reports of risks and benefits associated 
with the use of vaginal mesh kits use of these products 
spread rapidly worldwide. In retrospect, one may argue 
that early centralization to specialized high-volume cent-
ers rather than widespread dissemination of mesh pro-
cedures could have prevented some complications and 
individual suffering. It would be inherently difficult to 
randomize patients between high-volume centers and 
clinics with lesser volumes due to geographic and social 
considerations. We must, therefore, rely on analyses from 
observational studies, such as the present one, to obtain 
information on the long-term effects of surgical volumes. 
Classification of the procedure was homogenous since all 
operations used an identical mesh kit performed in a stand-
ardized manner. There is an inevitable loss to follow-up 
when performing long-term clinical cohort studies. We 
believe that number of patients lost to follow-up in the pre-
sent cohorts were not unusual with only minor differences 
between the single- and multi-center cohort suggesting a 
limited selection bias. A weakness of the study is that nei-
ther cohort was large enough to perform sub-analyses on 
possible predictors of both positive and negative outcomes 
with adequate statistical strength and precision. Factors 
such as pre-existing mood disorders, functional pain syn-
dromes, smoking, obesity and previous pelvic surgery, 
may influence surgical outcomes but need further studies 
to understand the mechanisms involved [28, 29].
In summation, our data suggest that despite the high 
objective and subjective long-term effectiveness of the 
procedure in both regular use and at a high-volume center, 
centralizing the use of mesh kit procedures had clear clini-
cal benefits. A reduction of secondary interventions by 
more than half when a standardized capturing-device 
guided transvaginal mesh was used at a high-volume 
center is an important advantage for patients and health 
care system alike. In countries where products similar to 
the one used in the present study remain in use, one may, 
therefore, advocate that mesh kit procedures should be 
centralized to high-volume center to minimize complica-
tions and secondary interventions.
Acknowledgements Statistical analyses were performed in collabora-
tion with statistician Fredrik Johansson, M.Sc, Department of Clinical 
Sciences Medical Library, Karolinska Institute Danderyd Hospital, 
Stockholm, Sweden.
141Archives of Gynecology and Obstetrics (2021) 303:135–142 
1 3
Author contributions CF: investigator, project development, patient 
examination, and critical revision of manuscript; DA: investigator, 
project development, and critical revision of manuscript; GP: inves-
tigator, patient examination, data collection, and statistical analysis; 
PRS: investigator, data collection; TM: investigator, data collection; 
EM: principle investigator, study design, project development, patient 
examination, statistical analysis, and manuscript writing.
Funding Open access funding provided by Karolinska Institute. Chris-
tian Falconer has received speaking and advisory honoraria from Bos-
ton Scientific and Johnson & Johnson. Daniel Altman has received 
speaking and advisory honoraria from Gedeon Richter, Pfizer, Astel-
las, Invent Medic and Gynecare. Georgios Poutakidis: None. Päivi 
Rahkola-Soisalo has received funding for congress trips from Johnson 
& Johnson and Astellas. Tomi Mikkola has received speaking and advi-
sory honoraria from Astellas and Contura. Edward Morcos: None. The 
single-center study was financially supported by hospital administered 
funds and received no external financial support. The multicenter study 
was supported by an investigator-initiated grant from Boston Scientific, 
grants from the Finnish Medical Foundation and the Swedish Research 
Council.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Vu MK, Letko J, Jirschele K, Gafni-Kane A, Nguyen A, Du H, 
Goldberg RP (2012) Minimal mesh repair for apical and anterior 
prolapse: initial anatomical and subjective outcomes. Int Urogy-
necol J 23(12):1753–1761
 2. Altman D, Mikkola TS, Bek KM, Rahkola-Soisalo P, Gunnarsson 
J, Engh ME, Falconer C, Nordic TVM group (2016) Pelvic organ 
prolapse repair using the Uphold™ Vaginal Support System: a 
1-year multicenter study. Int Urogynecol J 27(9):1337–1345
 3. Gutman RE, Rardin CR, Sokol ER, Matthews C, Park AJ, Iglesia 
CB, Geoffrion R, Sokol AI, Karram M, Cundiff GW, Blomquist 
JL, Barber MD (2017) Vaginal and laparoscopic mesh hyster-
opexy for uterovaginal prolapse: a parallel cohort study. Am J 
Obstet Gynecol 216(1):38.e1–38.e11
 4. Morcos E, Altman D, Hunde D, Falconer C, Nordic TVM group 
(2018) Comparison of single- versus multicenter outcomes for 
pelvic organ prolapse repair using a mesh-capturing device. Int 
Urogynecol J 29(1):91–97
 5. Lo TS, Pue LB, Tan YL, Hsieh WC, Kao CC, Uy-Patrimonio 
MC (2019) Anterior-apical single-incision mesh surgery (uphold): 
1-year outcomes on lower urinary tract symptoms, anatomy and 
ultrasonography. Int Urogynecol J 30(7):1163–1172
 6. Allegre L, Debodinance P, Demattei C, Fabbro Peray P, Cayrac 
M, Fritel X, Courtieu C, Fatton B, de Tayrac R (2019) Clinical 
evaluation of the Uphold LITE mesh for the surgical treatment 
of anterior and apical prolapse: a prospective, multicentre trial. 
Neurourol Urodyn 38(8):2242–2249
 7. Gillor M, Langer S, Dietz HP (2019) A long-term comparative 
study of Uphold™ transvaginal mesh kit against anterior colpor-
rhaphy. Int Urogynecol J. https ://doi.org/10.1007/s0019 2-019-
04106 -5
 8. Rahkola-Soisalo P, Mikkola TS, Altman D, Falconer C, Nordic 
TVM Group (2019) Pelvic organ prolapse repair using the uphold 
vaginal support system: 5-Year follow-up. Female Pelvic Med 
Reconstr Surg. 25(3):200–205
 9. FDA 2019: https ://www.fda.gov/news-event s/press -annou nceme 
nts/fda-takes -actio n-prote ct-women s-healt h-order s-manuf actur 
ers-surgi cal-mesh-inten ded-trans vagin al
 10. Filmann N, Walter D, Schadde E, Bruns C, Keck T, Lang H, 
Oldhafer K, Schlitt HJ, Schön MR, Herrmann E, Bechstein WO, 
Schnitzbauer AA (2019) Mortality after liver surgery in Germany. 
Br J Surg 106(11):1523–1529
 11. Aikoye A, Harilingam M, Khushal A (2015) The impact of high 
surgical volume on outcomes from laparoscopic (totally extra 
peritoneal) inguinal hernia repair. J Clin Diagn Res 9(6):15–16
 12. Chan JK, Gardner AB, Taylor K, Blansit K, Thompson CA, 
Brooks R, Yu X, Kapp DS (2015) The centralization of robotic 
surgery in high-volume centers for endometrial cancer patients–a 
study of 6560 cases in the US. Gynecol Oncol 138(1):128–132
 13. Vanthoor J, Thomas A, Tsaur I, Albersen M, in collaboration with 
the European Reference Network for rare urogenital diseases, and 
complex conditions (eUROGEN) (2019) Making surgery safer by 
centralization of care: impact of case load in penile cancer. World 
J Urol. https ://doi.org/10.1007/s0034 5-019-02866 -9
 14. Paraskevas KI (2019) The effect of centralization of abdominal 
aortic aneurysm repair procedures on perioperative outcomes. 
Ann Transl Med. https ://doi.org/10.21037 /atm.2019.05.71
 15. Tol JA, van Gulik TM, Busch OR, Gouma DJ (2012) Centraliza-
tion of highly complex low-volume procedures in upper gastro-
intestinal surgery. A summary of systematic reviews and meta-
analyses. Dig Surg 29(5):374–383
 16. Fisher AV, Ma Y, Wang X, Campbell-Flohr SA, Rathouz PJ, 
Ronnekleiv-Kelly SM, Abbott DE, Weber SM (2019) National 
trends in centralization of surgical care and multimodality therapy 
for pancreatic adenocarcinoma. J Gastrointest Surg. https ://doi.
org/10.1007/s1160 5-019-04361 -3
 17. Lundström NR, Berggren H, Björkhem G, Jögi P, Sunnegârdh J 
(2000) Centralization of pediatric heart surgery in Sweden. Pedi-
atr Cardiol 21(4):353–357
 18. Markar SR, Karthikesalingam A, Thrumurthy S, Low DE (2012) 
Volume-outcome relationship in surgery for esophageal malig-
nancy: systematic review and meta-analysis 2000–2011. J Gas-
trointest Surg 16(5):1055–1063
 19. Bump RC, Mattiasson A, Bø K, Brubaker LP, DeLancey JO, 
Klarskov P, Shull BL, Smith AR (1996) The standardization of 
terminology of female pelvic organ prolapse and pelvic floor dys-
function. Am J Obstet Gynecol 175(1):10–17
 20. Barber MD, Walters MD, Bump RC (2005) Short forms of two 
condition-specific quality-of-life questionnaires for women 
with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet 
Gynecol 193(1):103–113
 21. Rogers RG, Kammerer-Doak D, Villarreal A, Coates K, Qualls C 
(2001) A new instrument to measure sexual function in women 
with urinary incontinence or pelvic organ prolapse. Am J Obstet 
Gynecol 184(4):552–558
142 Archives of Gynecology and Obstetrics (2021) 303:135–142
1 3
 22. Wagemakers SH, van der Velden JM, Gerlich AS, Hindriks-Keeg-
stra AW, van Dijk JFM, Verhoeff JJC (2019) A systematic review 
of devices and techniques that objectively measure patients’ pain. 
Pain Physician 22(1):1–13
 23. de Tayrac R, Faillie JL, Gaillet S, Boileau L, Triopon G, Letouzey 
V (2012) Analysis of the learning curve of bilateral anterior sac-
rospinous ligament suspension associated with anterior mesh 
repair. Eur J Obstet Gynecol Reprod Bio 165(2):361–365
 24. Jeffery ST, Kortz BS, Muavha D, Stolwijk NN, Ras L, Roovers 
JWR (2018) Morbidity of a single incision transvaginal mesh to 
correct apical prolapse. J Minim Invasive Gynecol. https ://doi.
org/10.1016/j.jmig.2018.12.007
 25. Withagen MI, Vierhout ME, Hendriks JC, Kluivers KB, Milani 
AL (2011) Risk factors for exposure, pain, and dyspareunia 
after tension-free vaginal mesh procedure. Obstet Gynecol 
118:629–636
 26. Elmér C, Falconer C, Hallin A, Larsson G, Ek M, Altman D, Nor-
dic Transvaginal Mesh Group (2012) Risk factors for mesh com-
plications after trocar guided transvaginal mesh kit repair of ante-
rior vaginal wall prolapse. Neurourol Urodyn 31(7):1165–1169
 27. Altman D, Falconer C (2007) Perioperative morbidity using 
transvaginal mesh in pelvic organ prolapse repair. Obstet Gynecol 
109(2):303–308
 28. Parreira P, Maher CG, Steffens D, Hancock MJ, Ferreira ML 
(2018) Risk factors for low back pain and sciatica: an umbrella 
review. Spine J 18(9):1715–1721. https ://doi.org/10.1016/j.spine 
e.2018.05.018
 29. Karppinen A, Ritvonen E, Roine R, Sintonen H, Vehkavaara S, 
Kivipelto L, Grossman AB, Niemelä M, Schalin-Jäntti C (2016) 
Health-related quality of life in patients treated for nonfunctioning 
pituitary adenomas during the years 2000–2010. Clin Endocrinol 
(Oxf) 84(4):532–539. https ://doi.org/10.1111/cen.12967 
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
